BCAX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWBicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Nov 9, 2026

8-K

Bicara Therapeutics Inc. Enters Sub-Sublease Agreement for New Corporate Headquarters

Aug 25, 2026

8-K

Bicara Therapeutics Reports Second Quarter 2026 Financial Results and Announces Strategic Leadership Transitions

Aug 11, 2026

8-K

Bicara Therapeutics Appoints Jeremy Bender and Christy Oliger to Board of Directors

Jul 28, 2026

8-K

Bicara Therapeutics Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 10, 2026

8-K

Bicara Therapeutics Announces Three-Year Follow-Up Data for Ficerafusp Alfa in 1L R/M HPV-Negative HNSCC

May 21, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Feb 25, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $150,000,000 | Bank: Morgan Stanley, TD Cowen, BofA Securities, Cantor, Stifel

Feb 24, 2026

424B5

November 2025 ATM | Offering amount: $150,000,000

Nov 26, 2025

424B4

SHARE RESALE REGISTRATION | Shares amount: 17,500,000 | Share price: $18 | Offering amount: $315,000,000

Sep 13, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 11, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 30, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Feb 24, 2026

S-3

October 2025 SHELF & ATM

Oct 3, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 28, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Sep 13, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

Ownerships

TYPE

HEADLINE

FILED AT

144

Form 144 - Report of proposed sale of securities

Oct 21, 2026

SCHEDULE 13G/A

T. Rowe Price Investment Management, Inc. (Filed by)

Oct 7, 2026

Cohlhepp Ryan (Reporting)

Sep 10, 2026

144

Form 144 - Report of proposed sale of securities

Sep 8, 2026

144

Form 144 - Report of proposed sale of securities

Sep 8, 2026

Larson Jennifer (Reporting)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 28, 2025

CORRESP

Form CORRESP - Correspondence

Nov 24, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 13, 2024

CORRESP

Form CORRESP - Correspondence

Sep 10, 2024

CORRESP

Form CORRESP - Correspondence

Sep 10, 2024

CORRESP

Form CORRESP - Correspondence

Sep 3, 2024

Bicara Therapeutics Inc. Common Stock BCAX · SEC Filings